Your personalized research feed is ready.
Bassetti M, Giacobbe DR, Vena A et al. · Lancet Infectious Diseases · 2024
In this multicenter RCT, ceftazidime-avibactam demonstrated significantly improved 30-day all-cause mortality compared to polymyxin-based regimens for CR-KP bloodstream infections, with a favorable safety profile across 187 patients enrolled at 14 centers.
Wang X, Patel S, Okonkwo C et al. · Critical Care Medicine · 2024
A transformer-based early warning system for sepsis-3 was externally validated across 42 ICUs, achieving AUROC 0.89 (95% CI 0.87–0.91) for 6-hour early prediction, outperforming SOFA-based screening across all subgroups.
Nakamura K, Chen L, Hoffmann R et al. · Blood Advances · 2024
CD4+ T-cell recovery below 200 cells/μL at day +100 post-alloHSCT was independently associated with 4.8-fold increased risk of invasive fungal infections. Anti-fungal prophylaxis duration should be individualized based on immune reconstitution kinetics.
Johnson AB, Smith KL, Lee JY et al. · Open Forum Infectious Diseases · 2023
AUC-guided vancomycin dosing reduced acute kidney injury by 31% compared to trough-only monitoring in MRSA bacteremia without compromising clinical cure rates, supporting adoption of pharmacokinetic-based monitoring protocols.